查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493216

大麻藥品市場規模、佔有率、趨勢分析報告：按品牌類型、地區、細分市場預測，2024-2030 年

Cannabis Pharmaceuticals Market Size, Share & Trends Analysis Report By Brand Type (Sativex, Epidiolex, Other Brands), By Region (North America, Middle East And Africa, Asia Pacific, Europe), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

大麻藥品市場成長與趨勢：

Grand View Research, Inc. 的一項新研究顯示，到 2030 年，全球大麻藥品市場規模預計將達到 1,024 億美元，2024 年至 2030 年複合年成長率為 53.3%。

大麻在各種醫療應用中的使用不斷增加正在推動全球大麻藥物市場的成長。例如，大麻被廣泛用於治療患有帕金森氏症、癌症、關節炎和阿茲海默症慢性疾病以及憂鬱症、焦慮症和癲癇症等神經系統問題的患者。此外，慢性疼痛和疼痛管理療法的疾病負擔正在增加。因此，有效緩解疼痛的大麻產品的消費量正在增加。

近年來，由於醫療用途的全球接受度和合法化程度的提高，市場發生了重大變化。這一發展導致大麻藥物專利申請顯著增加。例如，2023年10月，專注於創造中樞神經神經病變和罕見疾病治療方法的臨床階段專業製藥公司SciSparc Ltd.提交了大麻素和N-醯基乙醇胺組合的專利申請（以下簡稱「我們」）。該專利已正式受理。該專利由澳洲智慧財產局授予，該機構是負責管理智慧財產權和專利法的澳洲政府機構。接受此類專利對於促進創新、幫助企業保護其發明以及鼓勵進一步的研究和開發至關重要。隨著大麻素的藥用價值得到廣泛認可，並且有可能為世界各地的患者提供新的治療選擇，這一趨勢預計將持續下去。

此外，大麻產業的各個公司和研究機構正在進行研究，以檢驗與 CBD 產品相關的聲明，這正在推動市場成長。為了滿足不斷成長的消費者需求而採用創新產品進一步支持了這一趨勢。根據美國食品藥物管理局(FDA) 2023 年 2 月發表的一項研究，FDA 推薦 Epidiolex（一種大麻二酚 (CBD) 的精製形式）用於治療患有腸漏症候群或Dravet 症候群的2 歲以下患者的癲癇發作年齡及以上核准。 FDA 也批准 Marinol 和 Syndros 在美國用於醫療用途。這些藥物已被核准用於改善癌症化療引起的噁心，並控制可能導致愛滋病患者體重減輕的厭食症。 2021 年 11 月，科羅拉多州立大學成立了一個專注於 CBD 的新研究中心。同月，Greenrise Global Brands, Inc. 的子公司 AMP Alternative Medical Products GmbH 在德國市場推出了屈大麻酚產品。

此外，公司正在實施多樣化的策略來增加其在市場上的影響力。例如，2024 年 3 月，製藥業大麻素領域的 Brains Bioceuticals（也固體Brains Bio）宣布全球首次生產用作活性藥物成分（API）的四氫大麻酚（THC）。結果。 2021年11月，生物製藥公司Avicana與一家知名的阿根廷製藥公司簽署了智慧財產權（IP）和分銷協議。作為該協議的一部分，Avicanna 將授予其專有的 10% CBD 藥物配方非獨家許可。

大麻藥品市場報告亮點

  • 按品牌類型分類，由於醫療保健專業人員和患者對藥用大麻的需求很高，Epidiolex 細分市場在 2023 年佔據了銷售佔有率。
  • 2023年，由於大麻消費量增加、對大麻及其產品的認知和積極態度不斷增強，歐洲以41.9%的收益佔有率主導整個市場。北美是最早將醫療和娛樂大麻使用合法化的地區之一。
  • 該領域的一些主要企業包括 Jazz Pharmaceuticals, Inc.、AbbVie, Inc.、Insys Therapeutics, Inc. 和 Bausch Health Companies, Inc.。

目錄

第1章 大麻藥品市場：調查方法與範圍

第2章 大麻藥品市場：執行概述

  • 市場展望
  • 分部展望
  • 競爭考察

第3章 大麻藥品市場：變數、趨勢、範圍

  • 市場體系展望
  • 市場動態
  • 大麻藥品市場分析工具

第4章 大麻藥品市場：品牌類型、估計與趨勢分析

  • 2023年及2030年品牌類型市場佔有率
  • 細分儀表板
  • 按品牌類型分類的全球大麻藥品市場展望
  • 2018-2030年市場規模、預測及趨勢分析

第5章 大麻藥品市場：區域估計與趨勢分析

  • 2023 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 按地區分類的全球市場概述
  • 2018-2030年市場規模、預測及趨勢分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 荷蘭
    • 義大利
    • 西班牙
    • 克羅埃西亞
    • 波蘭
    • 捷克共和國
    • 瑞士
  • 亞太地區
    • 日本
    • 澳洲
    • 紐西蘭
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 烏拉圭
    • 智利
    • 秘魯
  • 中東/非洲
    • 南非
    • 以色列

第6章 競爭狀況

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 2023年主要企業市場佔有率分析
    • Canopy Growth Corporation
    • Jazz Pharmaceuticals, Inc.
    • AbbVie, Inc.
    • Insys Therapeutics, Inc.
    • Bausch Health Companies, Inc.
Product Code: GVR-4-68038-473-4

Cannabis Pharmaceuticals Market Growth & Trends:

The global cannabis pharmaceuticals market size is expected to reach USD 102.4 billion by 2030, expanding at a CAGR of 53.3% from 2024 to 2030, according to a new study by Grand View Research, Inc. Growing use of cannabis in various medical applications is driving the global pharmaceutical cannabis market growth. For instance, cannabis is widely used for treating patients suffering from chronic conditions, such as Parkinson's disease, cancer, arthritis, and Alzheimer's disease, as well as neurologic problems, such as depression, anxiety, & epilepsy. Moreover, there is a growing disease burden of chronic pain and pain management therapies. This, in turn, is increasing cannabis product consumption as it is effective in pain management.

The market has undergone substantial changes in recent years, driven by increased global acceptance and legalization for medical use. This development has led to a notable rise in patent applications for cannabis-based pharmaceuticals. For instance, in October 2023, SciSparc Ltd., a specialized clinical-stage pharmaceutical company focusing on creating treatments for central nervous system disorders and rare diseases, announced that its patent application for the Combinations of Cannabinoids and N-Acylethanolamines (the "Patent") had been officially accepted. The patent was awarded by IP Australia, the Australian government agency responsible for managing intellectual property rights and patent legislation. Accepting such patents is vital for promoting innovation, allowing companies to safeguard their inventions and stimulate further research and development. This trend is expected to persist as the medicinal benefits of cannabinoids gain wider acknowledgment, potentially offering new treatment options for patients worldwide.

Furthermore, various companies and research institutes in the cannabis industry are conducting research studies to validate claims associated with CBD products, which is fueling market growth. This trend is further supported by the introduction of innovative products to meet the increasing consumer demand. According to the U.S. Food and Drug Administration (FDA) study published in February 2023, the FDA has given its approval to Epidiolex, a medication that contains a refined version of cannabidiol (CBD), for the treatment of seizures linked to Lennox-Gastaut syndrome or Dravet syndrome in patients aged 2 years and above. The FDA has also authorized the use of Marinol and Syndros for medical purposes in the U.S. These medications are approved for improving nausea caused by cancer chemotherapy and for managing anorexia leading to weight loss in patients with AIDS. In November 2021, Colorado State University inaugurated a new research center dedicated to CBD. Similarly, in the same month, AMP Alternative Medical Products GmbH, a subsidiary of Greenrise Global Brands, Inc., launched a Dronabinol product in the German market.

Moreover, companies are implementing diverse strategies to enhance their market presence. For instance, in March 2024, Brains Bioceutical Corp, also known as Brains Bio, a company in the pharmaceutical industry's cannabinoid sector, revealed its achievement in developing the world's first solid form of Tetrahydrocannabinol (THC) for use as an Active Pharmaceutical Ingredient (API). In November 2021, Avicanna, a biopharmaceutical firm, finalized an intellectual property (IP) and distribution agreement with a well-established pharmaceutical company in Argentina. As part of this agreement, Avicanna is expected to grant a nonexclusive license for its proprietary 10% CBD pharmaceutical drug preparation.

Cannabis Pharmaceuticals Market Report Highlights:

  • Based on brand type, Epidiolex segment accounted for the revenue share in 2023 owing to the high demand among healthcare practitioners and patients for medicinal cannabis
  • In 2023, Europe dominated the overall market with a revenue share of 41.9% owing to increasing cannabis consumption, as well as rising awareness and positive attitude towards cannabis and its products. North America was among the first regions to legalize the use of medical and recreational cannabis.
  • Some of the major players operating in this space are Jazz Pharmaceuticals, Inc., AbbVie, Inc., Insys Therapeutics, Inc., Bausch Health Companies, Inc.

Table of Contents

Chapter 1. Cannabis Pharmaceuticals Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Brand Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Cannabis Pharmaceuticals Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Brand type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cannabis Pharmaceuticals Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Cannabis Pharmaceuticals Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cannabis Pharmaceuticals Market: Brand Type Estimates & Trend Analysis

  • 4.1. Brand Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Cannabis Pharmaceuticals Market by Brand Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Sativex
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Epidiolex
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Brands
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cannabis Pharmaceuticals Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.5. North America
    • 5.5.1. U.S.
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Canada
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Europe
    • 5.6.1. UK
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Germany
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.3. France
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.4. Netherlands
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework/ reimbursement structure
      • 5.6.4.3. Competitive scenario
      • 5.6.4.4. Netherlands market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.5. Italy
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework/ reimbursement structure
      • 5.6.5.3. Competitive scenario
      • 5.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.6. Spain
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework/ reimbursement structure
      • 5.6.6.3. Competitive scenario
      • 5.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.7. Croatia
      • 5.6.7.1. Key country dynamics
      • 5.6.7.2. Regulatory framework/ reimbursement structure
      • 5.6.7.3. Competitive scenario
      • 5.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.8. Poland
      • 5.6.8.1. Key country dynamics
      • 5.6.8.2. Regulatory framework/ reimbursement structure
      • 5.6.8.3. Competitive scenario
      • 5.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.9. Czech Republic
      • 5.6.9.1. Key country dynamics
      • 5.6.9.2. Regulatory framework/ reimbursement structure
      • 5.6.9.3. Competitive scenario
      • 5.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.10. Switzerland
      • 5.6.10.1. Key country dynamics
      • 5.6.10.2. Regulatory framework/ reimbursement structure
      • 5.6.10.3. Competitive scenario
      • 5.6.10.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Asia Pacific
    • 5.7.1. Japan
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Australia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. New Zealand
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Latin America
    • 5.8.1. Brazil
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Regulatory framework/ reimbursement structure
      • 5.8.1.3. Competitive scenario
      • 5.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Mexico
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework/ reimbursement structure
      • 5.8.2.3. Competitive scenario
      • 5.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.3. Argentina
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework/ reimbursement structure
      • 5.8.3.3. Competitive scenario
      • 5.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.4. Colombia
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Regulatory framework/ reimbursement structure
      • 5.8.4.3. Competitive scenario
      • 5.8.4.4. Colombia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.5. Uruguay
      • 5.8.5.1. Key country dynamics
      • 5.8.5.2. Regulatory framework/ reimbursement structure
      • 5.8.5.3. Competitive scenario
      • 5.8.5.4. Uruguay market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.6. Chile
      • 5.8.6.1. Key country dynamics
      • 5.8.6.2. Regulatory framework/ reimbursement structure
      • 5.8.6.3. Competitive scenario
      • 5.8.6.4. Chile market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.7. Peru
      • 5.8.7.1. Key country dynamics
      • 5.8.7.2. Regulatory framework/ reimbursement structure
      • 5.8.7.3. Competitive scenario
      • 5.8.7.4. Peru market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. MEA
    • 5.9.1. South Africa
      • 5.9.1.1. Key country dynamics
      • 5.9.1.2. Regulatory framework/ reimbursement structure
      • 5.9.1.3. Competitive scenario
      • 5.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.9.2. Isarel
      • 5.9.2.1. Key country dynamics
      • 5.9.2.2. Regulatory framework/ reimbursement structure
      • 5.9.2.3. Competitive scenario
      • 5.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2023
    • 6.3.4. Canopy Growth Corporation
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Jazz Pharmaceuticals, Inc.
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. AbbVie, Inc.
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Insys Therapeutics, Inc.
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Bausch Health Companies, Inc.
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America cannabis pharmaceuticals market, 2018 - 2030 (USD Million)
  • Table 3 North America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 4 U.S. cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 5 Canada cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 6 Europe cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 7 Europe cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 8 Germany cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 9 UK cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 10 Netherlands cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 11 France cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 12 Italy cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 13 Spain cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 14 Croatia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 15 Poland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 16 Czech Republic cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 17 Switzerland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 19 Asia Pacific cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 20 Japan cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 21 New Zealand cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 22 Australia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 23 South Korea cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 24 Latin America cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 25 Latin America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 26 Brazil cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 27 Argentina cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 28 Mexico cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 29 Uruguay cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 30 Colombia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 31 Chile cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 32 Peru cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 33 MEA cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 34 MEA cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 35 South Africa cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 36 Israel cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Cannabis pharmaceuticals market: market outlook
  • Fig. 9 Cannabis pharmaceuticals competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Cannabis pharmaceuticals market driver impact
  • Fig. 15 Cannabis pharmaceuticals market restraint impact
  • Fig. 16 Cannabis pharmaceuticals market strategic initiatives analysis
  • Fig. 17 Cannabis pharmaceuticals market: Brand type movement analysis
  • Fig. 18 Cannabis pharmaceuticals market: Brand type outlook and key takeaways
  • Fig. 19 Sativex market estimates and forecast, 2018 - 2030
  • Fig. 20 Epidiolex market estimates and forecast, 2018 - 2030
  • Fig. 21 Other brands market estimates and forecast, 2018 - 2030
  • Fig. 22 Global Cannabis pharmaceuticals market: Regional movement analysis
  • Fig. 23 Global Cannabis pharmaceuticals market: Regional outlook and key takeaways
  • Fig. 24 Global Cannabis pharmaceuticals market share and leading players
  • Fig. 25 North America market share and leading players
  • Fig. 26 Europe market share and leading players
  • Fig. 27 Asia Pacific market share and leading players
  • Fig. 28 Latin America market share and leading players
  • Fig. 29 Middle East & Africa market share and leading players
  • Fig. 30 North America, by country
  • Fig. 31 North America
  • Fig. 32 North America market estimates and forecasts, 2018 - 2030
  • Fig. 33 U.S.
  • Fig. 34 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 35 Canada
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 37 Europe
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 39 UK
  • Fig. 40 UK market estimates and forecasts, 2018 - 2030
  • Fig. 41 Germany
  • Fig. 42 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 43 Netherlands
  • Fig. 44 Netherlands market estimates and forecasts, 2018 - 2030
  • Fig. 45 France
  • Fig. 46 France market estimates and forecasts, 2018 - 2030
  • Fig. 47 Italy
  • Fig. 48 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 49 Spain
  • Fig. 50 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 51 Croatia
  • Fig. 52 Croatia market estimates and forecasts, 2018 - 2030
  • Fig. 53 Poland
  • Fig. 54 Poland market estimates and forecasts, 2018 - 2030
  • Fig. 55 Czech Republic
  • Fig. 56 Czech Republic market estimates and forecasts, 2018 - 2030
  • Fig. 57 Switzerland
  • Fig. 58 Switzerland market estimates and forecasts, 2018 - 2030
  • Fig. 59 Asia Pacific
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 61 Japan
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 63 South Korea
  • Fig. 64 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 65 New Zealand
  • Fig. 66 New Zealand market estimates and forecasts, 2018 - 2030
  • Fig. 67 Australia
  • Fig. 68 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 69 Latin America
  • Fig. 70 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 71 Brazil
  • Fig. 72 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 73 Mexico
  • Fig. 74 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 75 Argentina
  • Fig. 76 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 77 Colombia
  • Fig. 78 Colombia market estimates and forecasts, 2018 - 2030
  • Fig. 79 Uruguay
  • Fig. 80 Uruguay market estimates and forecasts, 2018 - 2030
  • Fig. 81 Chile
  • Fig. 82 Chile market estimates and forecasts, 2018 - 2030
  • Fig. 83 Peru
  • Fig. 84 Peru market estimates and forecasts, 2018 - 2030
  • Fig. 85 Middle East and Africa
  • Fig. 86 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Africa
  • Fig. 88 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 89 Israel
  • Fig. 90 Israel Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 91 Market position analysis of key market players - Cannabis pharmaceuticals market